Fig. 2: Longitudinal change in clinical outcomes from baseline in MAD.
Gray shading indicates the 13-week treatment period. Results at each visit were based on an ANCOVA model, fitted with change from baseline as a dependent variable, and with treatment group, baseline value and baseline CDR-GS as independent variables. Error bars reflect s.e. No statistical testing or multiple comparison adjustments were performed. a Number of participants by study week based on MMSE. Small differences in n were seen for RBANS and FAQ. FAQ was not collected at week 9. In a, at baseline, the number of participants with MMSE scores in the placebo group was n = 12; BIIB080 10 mg Q4W had an n = 6; BIIB080 30 mg Q4W had an n = 6; BIIB080 60 mg Q4W had an n = 9; and BIIB080 115 mg Q12W had an n = 13. In b, at baseline, the number of participants with RBANS scores in the placebo group was n = 12; BIIB080 10 mg Q4W had an n = 6; BIIB080 30 mg Q4W had an n = 6; BIIB080 60 mg Q4W had an n = 9; and BIIB080 115 mg Q12W had an n = 13. In c, at baseline, the number of participants with FAQ scores in the placebo group was n = 12; BIIB080 10 mg Q4W had an n = 6; BIIB080 30 mg Q4W had an n = 6; BIIB080 60 mg Q4W had an n = 9; and BIIB080 115 mg Q12W had an n = 13.
